Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pardoprunox Adjunct Therapy in Advanced PD
NCT00406588Phase 3Completed
- Sponsor
- Solvay
- Start
- Mar 2007
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Pardoprunox + Levodopa with Placebo + Levodopa (2 arms). Primary endpoint: Change from baseline to end of the maintenance period or at the early termination visit in 'off'-time at 12 weeks. Started Mar 2007; status: completed.
02
Drugs
pardoprunox
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00406588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00406588.